TRVI NASDAQ
Trevi Therapeutics, Inc.
1W: -6.1%
1M: -4.3%
3M: +33.1%
YTD: +19.1%
1Y: +118.9%
3Y: +451.0%
5Y: +587.4%
$14.21
+0.06 (+0.39%)
Weekly Expected Move ±6.3%
$12
$13
$14
$15
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.0B
52W Range5.38-16.12
Volume908,712
Avg Volume1,519,951
Beta1.08
Dividend—
Analyst Ratings
Company Info
CEOJennifer L. Good
Employees31
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-07
Websitetrevitherapeutics.com
195 Church Street
New Haven, CT 06510
US
New Haven, CT 06510
US
203 304 2499
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Latest News
Trevi outlines cash runway into 2030 as it plans to start Phase III IPF cough trials in Q1 2026
Trevi Therapeutics Q1 2026 Earnings Call Transcript
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Earnings Scheduled For May 5, 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cassella James V | A-Award | 215,000 | $10.56 | 2026-02-19 |
| Galletta Christopher | A-Award | 35,000 | $10.56 | 2026-02-19 |
| SCIASCIA THOMAS | A-Award | 85,000 | $10.56 | 2026-02-19 |
| GOOD JENNIFER L | A-Award | 675,000 | $10.56 | 2026-02-19 |
| Simon Farrell | A-Award | 160,000 | $10.56 | 2026-02-19 |